Clinicopathological significance of serum fractalkine in primary biliary cirrhosis

Kenichi Harada, Yuko Kakuda, Minoru Nakamura, Shinji Shimoda, Yasuni Nakanuma

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC patients, which is closely associated with chronic cholangitis. Aims: We investigated the association between serum fractalkine levels and clinicopathological findings in PBC patients. Methods: Liver biopsy specimens before ursodeoxycholic acid treatment and serum samples at the time of liver biopsy and 1 and 2 years after treatment were obtained from 68 PBC patients (M/F = 14/54). Serum fractalkine levels were measured by enzyme-linked immunosorbent assay, and their association with clinicopathological findings (liver function data, autoantibodies, cholangitis activity, hepatitis activity, fibrosis, bile duct loss, and orcein-positive granules) was analyzed. Results: Serum fractalkine levels were in the range of 0.1-33.2 ng/ml (average, 3.2 ng/ml). They were increased in PBC patients with high degrees of cholangitis activity, a mild degree of hepatitis activity, fibrosis, orcein-positive granules, and early stages. In cases with high serum fractalkine levels, those who exhibited good biochemical responses to treatment mostly showed improved serum fractalkine levels after treatment. Conclusion: Serum fractalkine levels of PBC patients were high in cases with marked cholangitis activity at early stages. In addition, they closely correlated with the effect of therapy, indicating that fractalkine plays a role in the pathogenesis of initial cholangitis in early stage PBC and consequent chronic cholangitis. Thus, our results suggest that fractalkine is a good candidate for molecular-targeted treatment.

Original languageEnglish
Pages (from-to)3037-3043
Number of pages7
JournalDigestive Diseases and Sciences
Volume58
Issue number10
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Chemokine CX3CL1
Biliary Liver Cirrhosis
Cholangitis
Serum
Bile Ducts
Hepatitis
Liver
Fibrosis
Therapeutics
Intrahepatic Bile Ducts
Biopsy
Ursodeoxycholic Acid
Autoantibodies
Enzyme-Linked Immunosorbent Assay
Inflammation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Gastroenterology

Cite this

Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. / Harada, Kenichi; Kakuda, Yuko; Nakamura, Minoru; Shimoda, Shinji; Nakanuma, Yasuni.

In: Digestive Diseases and Sciences, Vol. 58, No. 10, 01.10.2013, p. 3037-3043.

Research output: Contribution to journalArticle

Harada, Kenichi ; Kakuda, Yuko ; Nakamura, Minoru ; Shimoda, Shinji ; Nakanuma, Yasuni. / Clinicopathological significance of serum fractalkine in primary biliary cirrhosis. In: Digestive Diseases and Sciences. 2013 ; Vol. 58, No. 10. pp. 3037-3043.
@article{20441bba52ac4a4b8dabe07e33abeac9,
title = "Clinicopathological significance of serum fractalkine in primary biliary cirrhosis",
abstract = "Background: Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC patients, which is closely associated with chronic cholangitis. Aims: We investigated the association between serum fractalkine levels and clinicopathological findings in PBC patients. Methods: Liver biopsy specimens before ursodeoxycholic acid treatment and serum samples at the time of liver biopsy and 1 and 2 years after treatment were obtained from 68 PBC patients (M/F = 14/54). Serum fractalkine levels were measured by enzyme-linked immunosorbent assay, and their association with clinicopathological findings (liver function data, autoantibodies, cholangitis activity, hepatitis activity, fibrosis, bile duct loss, and orcein-positive granules) was analyzed. Results: Serum fractalkine levels were in the range of 0.1-33.2 ng/ml (average, 3.2 ng/ml). They were increased in PBC patients with high degrees of cholangitis activity, a mild degree of hepatitis activity, fibrosis, orcein-positive granules, and early stages. In cases with high serum fractalkine levels, those who exhibited good biochemical responses to treatment mostly showed improved serum fractalkine levels after treatment. Conclusion: Serum fractalkine levels of PBC patients were high in cases with marked cholangitis activity at early stages. In addition, they closely correlated with the effect of therapy, indicating that fractalkine plays a role in the pathogenesis of initial cholangitis in early stage PBC and consequent chronic cholangitis. Thus, our results suggest that fractalkine is a good candidate for molecular-targeted treatment.",
author = "Kenichi Harada and Yuko Kakuda and Minoru Nakamura and Shinji Shimoda and Yasuni Nakanuma",
year = "2013",
month = "10",
day = "1",
doi = "10.1007/s10620-013-2734-6",
language = "English",
volume = "58",
pages = "3037--3043",
journal = "Digestive Diseases and Sciences",
issn = "0163-2116",
publisher = "Springer New York",
number = "10",

}

TY - JOUR

T1 - Clinicopathological significance of serum fractalkine in primary biliary cirrhosis

AU - Harada, Kenichi

AU - Kakuda, Yuko

AU - Nakamura, Minoru

AU - Shimoda, Shinji

AU - Nakanuma, Yasuni

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Background: Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC patients, which is closely associated with chronic cholangitis. Aims: We investigated the association between serum fractalkine levels and clinicopathological findings in PBC patients. Methods: Liver biopsy specimens before ursodeoxycholic acid treatment and serum samples at the time of liver biopsy and 1 and 2 years after treatment were obtained from 68 PBC patients (M/F = 14/54). Serum fractalkine levels were measured by enzyme-linked immunosorbent assay, and their association with clinicopathological findings (liver function data, autoantibodies, cholangitis activity, hepatitis activity, fibrosis, bile duct loss, and orcein-positive granules) was analyzed. Results: Serum fractalkine levels were in the range of 0.1-33.2 ng/ml (average, 3.2 ng/ml). They were increased in PBC patients with high degrees of cholangitis activity, a mild degree of hepatitis activity, fibrosis, orcein-positive granules, and early stages. In cases with high serum fractalkine levels, those who exhibited good biochemical responses to treatment mostly showed improved serum fractalkine levels after treatment. Conclusion: Serum fractalkine levels of PBC patients were high in cases with marked cholangitis activity at early stages. In addition, they closely correlated with the effect of therapy, indicating that fractalkine plays a role in the pathogenesis of initial cholangitis in early stage PBC and consequent chronic cholangitis. Thus, our results suggest that fractalkine is a good candidate for molecular-targeted treatment.

AB - Background: Primary biliary cirrhosis (PBC), characterized by cholangitis and loss of intrahepatic small bile ducts, predominantly affects middle-aged females. We have reported that fractalkine expression associated with chronic inflammation is observed in the damaged bile ducts and periductal vessels of PBC patients, which is closely associated with chronic cholangitis. Aims: We investigated the association between serum fractalkine levels and clinicopathological findings in PBC patients. Methods: Liver biopsy specimens before ursodeoxycholic acid treatment and serum samples at the time of liver biopsy and 1 and 2 years after treatment were obtained from 68 PBC patients (M/F = 14/54). Serum fractalkine levels were measured by enzyme-linked immunosorbent assay, and their association with clinicopathological findings (liver function data, autoantibodies, cholangitis activity, hepatitis activity, fibrosis, bile duct loss, and orcein-positive granules) was analyzed. Results: Serum fractalkine levels were in the range of 0.1-33.2 ng/ml (average, 3.2 ng/ml). They were increased in PBC patients with high degrees of cholangitis activity, a mild degree of hepatitis activity, fibrosis, orcein-positive granules, and early stages. In cases with high serum fractalkine levels, those who exhibited good biochemical responses to treatment mostly showed improved serum fractalkine levels after treatment. Conclusion: Serum fractalkine levels of PBC patients were high in cases with marked cholangitis activity at early stages. In addition, they closely correlated with the effect of therapy, indicating that fractalkine plays a role in the pathogenesis of initial cholangitis in early stage PBC and consequent chronic cholangitis. Thus, our results suggest that fractalkine is a good candidate for molecular-targeted treatment.

UR - http://www.scopus.com/inward/record.url?scp=84885330956&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885330956&partnerID=8YFLogxK

U2 - 10.1007/s10620-013-2734-6

DO - 10.1007/s10620-013-2734-6

M3 - Article

C2 - 23765258

AN - SCOPUS:84885330956

VL - 58

SP - 3037

EP - 3043

JO - Digestive Diseases and Sciences

JF - Digestive Diseases and Sciences

SN - 0163-2116

IS - 10

ER -